🔗 Share this article

Given that the US undertakes historic revisions to its immunization recommendations, one figure has surfaced in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by questioning coronavirus vaccines throughout the global health crisis and has concentrated on potential fatalities after Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Schedule

Agency leaders had intended to unveil major revisions to the pediatric vaccination calendar in December, bringing the US with Denmark’s vaccine program, sources say – a significant shift that would place the US out of alignment with much of the world with little proof for public health gain. This reveal has been delayed until the coming year.

Rather than the top vaccines chief, Høeg is scheduled to speak at the gathering. She was recently named interim head of the FDA’s CDER, the fifth person to head the office this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position might represent a strengthened alliance between the drug and biologics centers as Høeg and Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for halting certain pediatric vaccine recommendations in the US to become more similar to Denmark's approach, a society with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

To date public appearances, she has continued to focus on vaccines – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Background

The appointee has no obvious experience in pharmaceutical research, regulation or administrative roles, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in managing a large organization. She has no expertise in industry regulation.”

Former heads of CBER would “grasp legal statutes and the research of medication creation”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who headed the center have had.”

CDER has an enormous portfolio at the FDA, the former commissioner pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division authorizes a multitude of generic drugs. There’s a biosimilars program, non-prescription drug unit and so forth, and every single one must be managed,” she noted. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant administrative aspect to the job, which supervises over 5,000 staff members. “It is a huge leadership role, if you do it right,” Woodcock concluded.

Official Statement and Contentious Initiatives

Regarding inquiries about Høeg’s fitness for the role and whether this selection represents increased cooperation among FDA leaders on vaccines, a representative responded that the “questions stem from incorrect premises”.

“Her resume aligns with the responsibilities of her job,” the representative said, noting the months Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a disputed one-day therapy clearance system that reportedly worried her former heads. “How are these therapies being selected for this expedited pathway? Who is making the decisions?” Howard asked. “There is a lot of secrecy occurring at the FDA right now.”

In general, he stated, “the FDA appears to be shifting towards less stringent rules of all drugs, aside from shots.”

Documented Track Record on Immunizations

With vaccines, Dr. Høeg has a clearer, if problematic, track record, some experts observe. She published a research paper using unconfirmed crowd-sourced reports to assess the rate of myocarditis after Covid vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the new government included revising guidelines for novel immunizations and discontinuing “unnecessary” immunizations, she stated after the election on a audio program. At the agency, Dr. Høeg has allegedly suggested preventing young men from getting COVID-19 vaccines.

“She’s an all-around dogmatist who starts off with her conclusions and reverse-engineers to fit the data in a very misleading, fraudulent way,” Howard said.

Consolidating Power and a “Push for Payback”

Høeg joined other skeptics, {like|